LCF9: Lung Adenocarcinoma

Curie Institute - Lung Cancer


Related Models
PDX model Engraftment
Host Strain Name Site Type Material Material Status Passage
Swiss Nude Crl:Nu(Ico)-foxn1nu
interscapular fat pad heterotopic tissue fragment Not Specified 16, 18, 3, 5
Not Specified Crl:NU(NCr)-Foxn1n
Not Specified Not Specified Not Specified Not Specified 5
Model Quality Control
Technique Description Passage
histology high concordance between xenograft and patient tumour 3
fingerprinting high concordance between xenograft and patient tumor 18
Publications
Title Sensitization Of EGFR Wild-Type Non-Small Cell Lung Cancer Cells To EGFR-Tyrosine Kinase Inhibitor Erlotinib.
Authors Raimbourg J, Joalland MP, Cabart M ... Lalier L.
Publication year 2017
Journal Sensitization of EGFR Wild-Type Non-Small Cell Lung Cancer Cells to EGFR-Tyrosine Kinase Inhibitor Erlotinib.
Patient
Sex male
Ethnicity not specified
Derived Model LCF9
Patient Tumor Collection For PDX Model
Collection (Current Model)
Age 65
Diagnosis Lung Adenocarcinoma
Type primary
PDX Mouse LCF9
Collection Site lung
Grade not specified
Stage t2,n1 ( Classification: tnm staging system 2004)
Sample ID Sample Type Engrafted Tumor Passage Data Type Data Available Platform Used Raw Data
LCF9p5:03/09/2009 Engrafted Tumor Passage 5 cytogenetics View data FISH Not Available
LCF9p16:19/05/2015 Engrafted Tumor Passage 16 copy number alteration View data CGH array Not Available
LCF9p16:19/05/2015 Engrafted Tumor Passage 16 mutation View data Targeted NGS Not Available

Sample ID:     Histology:     Tumor Type: Engrafted Tumor     Passage:     Platform:    

Drug Dose Response
Cisplatin 1.0mg/kg stable disease
Cisplatin 6.0mg/kg stable disease